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HEMATOPOIESIS AND STEM CELLS
Kruppel-like factor 7 overexpression suppresses hematopoietic stem and
progenitor cell function
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1Department of Pediatrics, Washington University, St Louis, MO; 2Department of Medicine, University of Florida, Gainesville, FL; 3Department of Medicine,
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Increased expression of Kruppel-like fac-
tor 7 (KLF7) is an independent predictor
of poor outcome in pediatric acute lym-
phoblastic leukemia. The contribution of
KLF7 to hematopoiesis has not been pre-
viously described. Herein, we character-
ized the effect on murine hematopoiesis
of the loss of KLF7 and enforced expres-
sion of KLF7. Long-term multilineage en-
graftment of Klf7/ cells was comparable
with control cells, and self-renewal, as
assessed by serial transplantation, was
not affected. Enforced expression of
KLF7 results in a marked suppression of
myeloid progenitor cell growth and a loss
of short- and long-term repopulating activ-
ity. Interestingly, enforced expression of
KLF7, although resulting in multilineage
growth suppression that extended to he-
matopoietic stem cells and common lym-
phoid progenitors, spared T cells and
enhanced the survival of early thymo-
cytes. RNA expression profiling of
KLF7-overexpressing hematopoietic pro-
genitors identified several potential tar-
get genes mediating these effects. Nota-
bly, the known KLF7 target Cdkn1a
(p21Cip1/Waf1) was not induced by KLF7,
and loss of CDKN1A does not rescue the
repopulating defect. These results sug-
gest that KLF7 is not required for normal
hematopoietic stem and progenitor
function, but increased expression, as
seen in a subset of lymphoid leukemia,
inhibits myeloid cell proliferation and pro-
motes early thymocyte survival. (Blood.
2012;120(15):2981-2989)
Introduction
Although current therapeutic protocols have achieved a cure rate
of  85% in pediatric patients with acute lymphoblastic leukemia
(ALL), outcomes for patients with persistent disease after induction
chemotherapy or who have relapsed disease are much worse.
Currently, more than half of children with relapsed ALL die from
the disease, and a study from the Children’s Oncology Group
demonstrated that the 5-year survival rate for children with an early
relapse ( 18 months from initial diagnosis) is only 21.0% 1.8%.1
The identification of patients with high-risk features and the need for
intensification of therapy is crucial to the management of such persons.
In an analysis of bone marrow cells of 187 children with ALL,
Flotho et al showed that the expression of Kruppel-like factor
7 (KLF7) was significantly elevated in patients with minimal
residual disease at day 19 of therapy and was an independent
predictor of leukemic relapse in a separate cohort of 99 patients.2
Minimal residual disease at day 19 of induction therapy is highly
predictive of high-risk disease and is a reliable marker of
chemotherapy-refractory leukemia.3 In addition, a 5.5-fold increase
in KLF7 expression was found in the bone marrow cells of patients
with imatinib-resistant CML compared with sensitive controls.4
The KLF family of transcription factors are involved in
regulating cellular growth and differentiation in multiple tissue
types. Furthermore, members of this family are involved in
numerous aspects of hematopoiesis, including the regulation of
erythropoiesis, lymphopoiesis, and myelopoiesis.5-7 KLF7 is impor-
tant for neurogenesis, and mice lacking KLF7 die perinatally with
severe neurologic defects.8 Although no specific role for KLF7 in
hematopoiesis has been previously reported, the loss of the closely
related family member KLF6 is associated with defective blood
cell production.9 Targets of KLF7 include known regulators of
hematopoietic stem and progenitor cell (HSPC) function, including
TRKA, CEBP/, and CDKN1A (p21Cip1/Waf1).8,10,11 Given the
association of KLF7 with resistant leukemia and the fact that other
members of the KLF family are involved in various aspects of
hematopoiesis, we hypothesized that KLF7 may play a role in
regulating normal HSPC function and may contribute to leukemo-
genesis or resistance to therapy. To test this hypothesis, we have
established Klf7/ fetal liver chimeras to address the effects of
loss of KLF7 on HSPC function. To model the overexpression of
KLF7 seen in resistant leukemia, we generated retroviral and
lentiviral vectors to overexpress KLF7 in HSPCs.
Methods
Mice
C57BL/6 mice (B6.SJL-Ptprc* Pep3b BoyJ) carrying Ly5.1 were obtained
from the The Jackson Laboratory. Cdkn1a-deficient mice (Ly5.2) were
generated as previously described12 and backcrossed  10 generations onto
a C57BL/6 background. Klf7/ mice (Ly 5.2) were a kind gift of Dr Susan
Dorsey at the University of Maryland. They were generated as previously
described.8 Sex- and age-matched mice 6-9 weeks of age were used in
transplant experiments, unless otherwise indicated, in accordance with the
guidelines of the Washington University Animal Studies Committee. Mice
were housed in a specific pathogen-free environment.
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Generation of fetal liver chimeras
Wild-type (WT; Ly5.1) or Klf7/ (Ly5.2) fetal liver cells were obtained by
performing timed matings and harvesting fetal livers at 13.5-14.5 days after
conception. Fetal liver cells were then passed through an 18-gauge needle to
obtain a single-cell suspension and frozen at80°C in freezing media (90%
FBS, 10% DMSO). Genotyping was performed on fetal tissue using PCR to
distinguish the mutant and WT alleles using Taq DNA polymerase
(Invitrogen) and the following cycling conditions: 95°C for 5 minutes, then
40 cycles of 95°C for 1 minute, 63°C for 1 minute and 72°C for 1 minute,
then 72°C for 10 minutes. Primers for the mutant and WT products,
respectively, were as follows: Neo/F: 5-GGAGAGGCTATTCGGCTAT-
GACTG-3; Neo/R: 5-CTCTTCGTCCAGATCATCCTGATC-3; EX1/F:
5-TTTCCTGGCAGTCATCTGCAC-3; EX1/R: 5- GGGTCTGTTTGT-
TTGTCAGTCTGT-3). Thawed cells were then washed in MEM- (Invit-
rogen) with 15% FBS and counted on a hemacytometer with trypan blue to
exclude dead cells. A total of 2 million live cells (from 2 or 3 pooled donors)
were mixed in a 1:1 ratio with competitor (Ly5.2) cells and injected
retro-orbitally into lethally irradiated (1000 cGy) recipient (Ly5.1/Ly5.2)
mice. Prophylactic antibiotics (trimethoprim-sulfamethoxazole; Alpharma)
were given for 2 weeks after transplantation. For serial transplants, bone
marrow was harvested from the femurs of primary recipients 3-6 months
after transplantation. Bone marrow from similar genotypes was pooled,
analyzed by flow cytometry for Ly5.1 and Ly5.2 to determine input
chimerism, and transplanted (3-4 million cells/recipient) into lethally
irradiated secondary or tertiary recipients.
KLF7 virus production
KLF7 overexpression was achieved using 2 different viral vectors: the
MSCV-IRES-GFP retroviral vector and the HIV-MND-GFP lentiviral
vector.13 The HIV-MND-GFP vector was modified to contain an internal
ribosomal entry site (IRES) upstream of GFP. The murine Klf7 coding
sequence (nucleotides 389-1294; NM_033563.2) was inserted into each
vector. For retrovirus production, 293T cells were transfected with the
Ecopak plasmid and the MSCV vector using the Calcium Phosphate
Transfection Kit (Invitrogen), following the manufacturer’s recommenda-
tions. A similar procedure was used to generate lentivirus, except that the
packaging plasmids pMD.G, pRSV-Rev and PMDLg were cotransfected
with the HIV-MND vectors.14 Viral supernatant was collected 48 and 72 hours
after transfection and, for lentivirus, concentrated by centrifugation at
76 000g for 1.5 hours at 4°C (SW32 rotor in Optima LE-80K ultracentri-
fuge; Beckman Coulter).
Retroviral transduction and transplantation of primary murine
hematopoietic progenitors
For experiments using MSCV virus, donor mice were treated with
5-fluorouracil (Sigma-Aldrich; 100 mg/kg intraperitoneally), and bone
marrow was harvested by centrifugation of femurs and tibias (3300g for
1 minute) 24 hours later. Cells were then plated in 6-well plates in
transfection media (MEM-, Invitrogen; with 15% FCS and a cytokine
cocktail [TPO 10 ng/mL, IL-3 10 ng/mL, SCF 100 ng/mL, and Flt3-L
50 ng/mL]). Virus was added at a multiplicity of infection of  10:1, and
cells were spun at (966g) for 90 minutes at 30°C in a Sorvall RT 7 centrifuge.
They were then placed in a 37°C incubator overnight, washed, and spun
again with fresh media and virus. After the second spinfection, cells were
allowed to rest at 37°C for at least 6 hours, then washed 1 time in media,
filtered, and resuspended in PBS with 0.1% BSA for transplantation. For
transplants, 2-3 million cells were injected retro-orbitally into lethally
irradiated (1000 cGy) recipient mice.
For the HIV-MND-GFP lentivirus, bone marrow cells were harvested
from donor mice by crushing leg bones, pelvis, and sternum in PBS 10% FCS
using a mortar and pestle. Cells were then filtered, counted, and incubated
with anti-CD117 beads (c-Kit, Miltenyi) following the manufacturer’s
instructions. Kit cells were isolated on an AutoMacs cell separator
(Miltenyi). The c-Kit cells were cultured in transfection media and
transduced by spinfection over 2 days, using an multiplicity of infection
of  10:1. Approximately 500 000 cells were transplanted per recipient.
CFU-C assay
Transduced bone marrow cells or fetal liver cells (25 000) were plated in
MethoCult 3434 (StemCell Technologies) and cultured for 7 days at 37°C in
a humidified chamber with 5% CO2. For colony formation (CFU), CFU-G,
CFU-GM, CFU-M, and BFU-E, cells were plated in base methylcellulose
(M3231, StemCell Technologies) with the addition of appropriate cytokines
(PeproTech; for CFU-G; G-CSF 100 ng/mL; for CFU-GM, GM-CSF
25 ng/mL and IL-3 10 ng/mL; for CFU-M, M-CSF 10 ng/mL; and for
BFU-E, Epo 2 U/mL, SCF 100 ng/mL and IL-3 10 ng/mL). The total
number of colonies and the percentage of GFP colonies were assessed
using an Olympus IX51 scope.
Flow cytometry
Peripheral blood was obtained by retro-orbital sampling, and blood counts
determined using a Hemavet (Drew Scientific) automated cell counter.
Spleen and thymus were harvested, and single-cell suspensions generated
using a dounce homogenizer. After lysis of red blood cells using Tris-
buffered ammonium chloride buffer, pH 7.2, cells were then stained in PBS
containing 1mM EDTA and 0.2% (weight/volume) BSA (FACS buffer)
with 1 or more of the following antibodies: anti–mouse CD45.1 (clone
A20), anti–mouse CD45.2 (clone 104), anti–mouse CD115 (clone AFS98),
anti–mouse/human CD45R (B220; clone RA3-6B2), anti–mouse CD3e
(clone 145-2C11), anti–mouse Ly-6G (Gr-1; clone RB6-8C5), anti–mouse
CD8a (clone 53-6.7, BioLegend), anti–mouse CD4 (clone GK1.5, BioLeg-
end), and anti–mouse CD3e (clone 145-2C11). All antibodies were obtained
from eBioscience, unless otherwise noted.
For the analysis of apoptosis, cells were stained for surface markers, then
resuspended in binding buffer (20mM HEPES, pH 7.4, 132mM NaCl, 6mM
KCl, 2.5mM CaCl2, 1mM MgCl2, 1.2mM Kh2PO4, 5.5mM glucose, and
0.5% BSA) with the addition of annexin V (BD Biosciences). After binding
15 minutes, cells were washed and resuspended in binding buffer with
DAPI for flow cytometry.
For the analysis of hematopoietic progenitor populations, bone marrow
cells were incubated with the following progenitor antibody panel: anti–
mouse Ly6A/E (Sca-1) PerCP-Cy5.5 (clone D7), anti–mouse CD117
(c-Kit) APC–eFluor 780 (clone 2B8), anti–mouse CD34 PE (clone HM34,
BioLegend), anti–mouse CD16/32 eFluor 450 (clone 93), anti–mouse
CD45.1 PE-Cy7 (clone A20), anti–mouse/human CD45R (B220) biotin
(clone RA3-6B2), anti–mouse CD3e biotin (clone 145-2C11), anti–mouse
Ly-6G (Gr-1) biotin (clone RB6–8C5), anti–mouse Ter119 biotin (clone
TER-119), and streptavidin eFluor 605NC. To measure common lymphoid
progenitors (CLP), bone marrow cells were incubated with anti–mouse
Ly6D PE (clone 49-H4; BD Biosciences PharMingen), anti–mouse CD27
PerCp-Cy5.5 (clone LG.3A10), anti–mouse/human CD45R (B220) PE-Cy7
(clone RA3-6B2), anti–mouse CD3e PE-Cy7 (clone 145-2C11), anti–
mouse Ly-6G (Gr-1) Pe-Cy7 (cone RB6-8C5), anti–mouse Ter119 PE-Cy7
(clone TER-119), anti–mouse CD135 APC (clone A2F10), anti–mouse
IL7R biotin (clone A7R34; a kind gift of Dr Deepta Bhattacharya,
Department of Immunology & Pathology, Washington University, St Louis,
MO), anti–mouse CD45.1 APC-eFluor 780 (clone A20), and streptavidin
eFluor 450). All staining was done on ice for 30 minutes, and cells were
then washed and incubated with secondary antibody, where indicated, for
an additional 30 minutes. Cells were analyzed on the Gallios Flow
Cytometer (Beckman Coulter) and analyzed using the FloJo Version 9.3.4
software (TreeStar).
RNA expression profiling
For RNA expression profiling of HSCs, bone marrow was pooled from
10 mice for each of the 3 experimental replicates. Cells were stained with
the progenitor antibody panel (with exception of the use of anti–mouse
CD150 [clone TC15-12F12.2, BioLegend], anti–mouse CD41 [clone
MWReg30; BD Biosciences PharMingen], and anti–mouse CD48 [clone
HM48-1, eBioscience]), and then c-Kit Sca-1 lineage CD150 CD41
CD48 cells were sorted using an iCyt Reflection cell sorter directly into
Trizol LS reagent (Invitrogen). For RNA expression profiling of Klf7/
HSPCs, bone marrow was harvested from fetal liver chimeras and stained
with the progenitor antibody panel. Kit Sca lineage (KLS) cells were
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sorted using a MoFlo cell sorter (Dako North America) directly into lysis
buffer, and RNA was prepared using the RNA XS column kit (Macherey-
Nagel) according to the manufacturer’s directions. For expression profiling
of KLF7 overexpressing HSPCs, bone marrow cells exposed to MSCV or
HIV-MND virus expressing KLF7 or GFP alone were harvested 72 hours
after transduction. KLS GFP cells were sorted using a MoFlo cell
sorter directly into lysis buffer, and RNA was prepared using the RNA
XS column kit. RNA was amplified using the NuGen Ovation system
(NuGen), and hybridized to the Affymetrix MoGene Version 1.0 ST
array. Data normalization using the Robust Multichip Average algo-
rithm, and detection P value determinations were made using the
Affymetrix Expression Console Version 1.1 software. Gene set enrichment was
performed using the gene set enrichment analysis Version 2.0 software (Broad
Institute). Submission of expression data can be found by following the link,
http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc 	 GSE40331.
Real-time quantitative RT-PCR
Real-time RT-PCR was performed using the TaqMan One-Step RT-PCR
Master Mix Reagents kit (Applied Biosystems) on a GeneAmp 5700 Sequence
Detection System (Applied Biosystems). The reaction mix consisted of
0.5-1 
L RNA, 10 
L RT-PCR mix, primer/probe, and 0.5 
L MultiScribe
reverse transcription and RNase inhibitor in a total reaction volume of
20 
L. Reactions were repeated in the absence of reverse transcription to
confirm that DNA contamination was not present. RNA content was
normalized to murine -actin. PCR conditions were 48°C for 30 minutes
and 95°C for 10 minutes, followed by 40 cycles of 95°C for 15 seconds and
60°C for 1 minute.
Primers and probes were as follows: -actin: forward: 5-ACCAACTG-
GGACGATATGGAGAAGA-3; reverse: 5-TACGACCAGAGGCATA-
CAGGGACAA-3; probe: 5-AGCCATGTACGTAGCCATCCA-3 (FAM/
TAMRA). KLF7: forward: 5-CCTGGCAGCAGACATGCCTTGA-3;
reverse: 5-AGGCGCCGGAAGCTCTCCTC-3; probe: 5-CGGCGGATC-
TCGGAGACCTT-3 (FAM/TAMRA).
The following TaqMan Gene Expression Assay (Applied Biosystems)
primer/probe reagents were used: KLF4: Mm00516104_m1; KLF6:
Mm00516184_m1; KLF9: Mm00495172_m1; KLF10: Mm00449812_m1;
CDKN1a: Mm00432448_m1; BCL2A1: Mm03646861_mH.
Statistics
Significance was determined using Prism Version 5.0 software (GraphPad).
Statistical significance of differences was calculated using 2-tailed Student t
tests, or 1- or 2-way ANOVA. P  .05 was considered significant. All data
are presented as mean  SEM except as noted.
Results
Loss of KLF7 does not impair HSPC repopulating activity
To assess KLF family gene expression in murine HSCs, we isolated
RNA from sorted KLS CD150 CD48 CD41 bone marrow cells
and performed RNA expression profiling. This cell population is
highly enriched for HSCs, with nearly one half of the cells having
long-term repopulating activity.15 Of the 17 KLF family members,
the majority were expressed at low but detectable levels, including
KLF7 (supplemental Table 1, available on the Blood Web site; see
the Supplemental Materials link at the top of the online article). In
agreement with these data, an RNA profiling study of HSCs and
their differentiated progeny by Chambers et al demonstrated
expression of KLF7 in the side population KLS cells.16
We next quantified KLF7 mRNA expression in different HSPC
subsets and selected mature hematopoietic lineages (supplemental
Figure 1). KLF7 expression was detected in all hematopoietic
lineages and HPSCs subsets. Interestingly, an  5-fold increase in
KLF7 expression was observed in the transition from CD4 CD8
(double-negative; DN) thymocytes to CD4 CD8 (double-
positive, DP) thymocytes.
Loss of KLF7 is embryonic lethal because of neurologic
defects.8 To assess the role of KLF7 in normal hematopoiesis, we
first analyzed HSPCs in Klf7/ fetal livers. The percentage of KLS
cells in Klf7/ fetal livers and their capacity to generate myeloid
colonies in vitro were similar to that observed in the fetal liver of
Klfl7/ siblings (Figure 1A-B). To assess in vivo HSPC function,
Figure 1. Loss of KLF7 does not affect bone marrow repopulating activity. The frequency of KLS (A) and colony-forming cells (B) in the fetal liver from 13.5-14.5-dpc
Klf7/ and Klf7/ embryos is shown. Data represent 2 or 3 independent experiments with 2 or 3 livers per genotype. Fetal liver chimeras were generated by transplanting
Klf7/, Klf7/, or Klf7/ fetal liver (Ly5.2) cells with an equal number of WT competitor fetal liver (Ly5.1) cells into irradiated congenic (Ly5.1/5.2) mice. (C) The percentage of
donor leukocytes at the indicated times. (D) The contribution of donor cells to B cells (B220), T cells (CD3e), neutrophils (Gr-1 high), and monocytes (Gr-1 CD115)
assessed 12 weeks after transplantation is shown for 1 representative experiment. Bone marrow was harvested from primary recipients at 12 weeks and serially transplanted.
Shown is donor contribution in secondary (E) or tertiary (F) recipients. Data represent 2 or 3 independent experiments for each genotype, with 4 or 5 mice per genotype per
experiment.
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we generated Klf7/ fetal liver chimeras. The contribution of
Klf7/ cells to multilineage engraftment was similar to control
cells at up to 12 weeks after transplantation (Figure 1C-D). To
assess the effects of KLF7 loss on HSC self-renewal, serial
transplantations were performed. Again, Klf7/ HSCs engrafted
secondary and tertiary recipients with equal efficiency to Klf7/
HSCs (Figure 1E-F).
To address the possibility that other KLF family members may
compensate for the loss of KLF7, we isolated Klf7/ and Klf7/
KLS cells from primary recipients 12 weeks after transplantation
and performed RNA expression profiling. Although modest differ-
ences in expression of certain KLF family members were initially
identified by expression profiling (supplemental Table 2), none of
these changes was validated by real time RT-PCR (supplemental
Figure 2). Thus, at least at the RNA level, compensatory expression
of other KLF family members was not induced by the loss of
KLF7. Collectively, these results suggest that KLF7 does not play
an essential role in normal hematopoiesis because HSCs lacking
KLF7 are able to engraft irradiated recipients and support multlin-
eage hematopoiesis to a similar extent as WT HSCs.
Overexpression of KLF7 inhibits in vitro myeloid colony
formation
To model the effects of overexpression of KLF7 on HSPC function,
we generated retroviral and lentiviral vectors that express KLF7.
First, we used a retroviral vector (MSCV-IRES-GFP) expressing
the murine KLF7 coding sequence to transduce primary mouse
bone marrow cells. Expression of KLF7 in transduced (GFP)
WT bone marrow cells was increased approximately 10-fold
compared with control cells (Figure 2A). After viral transduction of
whole bone marrow from 5-fluorouracil–treated WT mice, cells
were plated, unsorted, onto complete methylcellulose media to
assess in vitro myeloid colony-forming ability. Relative to the
initial transduction efficiency, the number of myeloid colonies
produced from KLF7-transduced cells compared with vector-alone
transduced cells was reduced 5.7  1.9–fold, demonstrating that
overexpression of KLF7 suppresses myeloid cell growth (Figure
2B-C). To further characterize the effects of KLF7 overexpression
on myeloid development, WT c-Kit selected cells were trans-
duced with lentivirus expressing KLF7 or GFP alone, and sorted
GFP cells were plated on complete methylcellulose media (Figure
2D). Again, enforced expression of KLF7 inhibited the formation of all
myeloid colony types, including CFU-G, CFU-M, CFU-GM,
and BFU-E.
Overexpression of KLF7 inhibits the repopulating ability
of HPSCs
We next assessed the repopulating activity of cells transduced with
KLF7 MSCV retrovirus by transplanting unsorted cells into
irradiated congenic recipients. Transduction efficiency was as-
sessed in vitro by measuring the percentage of KLS cells that
expressed GFP at 72 hours after transduction (Figure 3A, time
zero). The contribution of KLF7 transduced cells was markedly
suppressed at 6 and 12 weeks after transplantation (Figure 3A).
Furthermore, whereas control transduced cells produced both
myeloid and lymphoid lineage cells, minimal contribution of
KLF7-transduced cells was observed in all lineages, except T cells
(Figure 3B).
To obtain a more durable overexpression of KLF7, we repeated
these experiments using lentivirus expressing KLF7 or GFP alone.
We again observed an  10-fold increased expression of KLF7 in
transduced cells (Figure 3E). In experiments using a high multiplic-
ity of infection, resulting in high transduction efficiency ( 60%
transduced cells), overexpression of KLF7 was associated with
impaired radioprotection. Whereas all (12 of 12) recipients trans-
planted with control-transduced cells survived, only 42% (5 of 12) of
recipients of KLF7 transduced cells survived more than 2 weeks
after transplantation (P  .003). An analysis of moribund recipi-
ents revealed marked bone marrow hypocellularity indicative of
engraftment failure (data not shown).
When we performed these experiments using a reduced multi-
plicity of infection to achieve a lower transduction efficiency, all
recipient mice survived at least 6 weeks. Again, whereas control-
transduced cells were readily detected at near input levels (on
average, 40% of nucleated blood cells), minimal contribution of
KLF7-transduced cells was observed in all lineages, except T cells
(Figure 3C-D; see Figure 6). Importantly, no cases of leukemia
were observed during the 3-month observation period. Thus,
overexpression of KLF7 is not sufficient to induce leukemia in
mice in the short term.
To investigate whether KLF7 overexpression impairs homing to
the bone marrow, we sorted GFP KLS bone marrow cells from
cultures transduced with KLF7 or control lentivirus, and injected
the cells into lethally irradiated recipient mice. Twenty hours later,
a similar number of GFP cells were recovered from the bone
marrow of mice transplanted with KLF7 or control lentivirus-
transduced cells (Figure 3F). Thus, the lack of engraftment of
KLF7 overexpressing cells is not the result of impaired homing of
KLF7 overexpressing cells to the bone marrow.
Figure 2. KLF7 overexpression inhibits in vitro myeloid colony formation.
WT bone marrow cells from 5-fluorouracil–treated donors were transduced with
MSCV-IRES-GFP expressing KLF7 or vector alone. (A) Transduced (GFP) cells
were isolated 72 hours after transduction, and the expression of KLF7 (relative to
-actin) was measured by real-time RT-PCR. Data represent 2 independent experi-
ments. *P 	 .033. Unsorted bone marrow cells exposed to control or KLF7 retrovirus
were plated in methylcellulose and cultured for 7 days. (B) Representative photomi-
crograph showing the GFP colonies (top panel) and total colonies (bottom panel).
Original magnification 10. (C) The percentage of GFP colonies relative to the input
percentage of GFP cells. *P 	 .026. Data represent the average  SEM of
2 independent experiments, each plated in duplicate. (D) GFP sorted cells from
lentivirally transduced c-Kit cells were plated in complete methylcellulose, and
colonies were scored by morphology after 7 days of growth.
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Overexpression of KLF7 suppresses bone marrow stem and
progenitor cells
To determine whether KLF7 overexpression suppresses hematopoi-
esis at the hematopoietic stem cell or more committed progenitor
level, we characterized the contribution of KLF7-transduced cells
to defined hematopoietic progenitor cell populations in mice 6 weeks
after transplantation. KLF7 overexpression was associated with a
marked suppression of all hematopoietic progenitor populations,
including HSCs (Figure 4). Of note, despite the relatively high
contribution of KLF7-transduced cells to the T-cell lineage,
KLF7-transduced common lymphoid progenitors (CLPs) were
markedly reduced.
KLF7 suppression of HSPCs is not mediated by Cdkn1a
Previous studies have shown that Cdkn1a (p21 cip1/waf1) is a
direct transcriptional target of KLF7, and overexpression of KLF7
in neuronal cells results in increased CDKN1A expression.8,17
Given the known role of CDKN1A in regulating HSPC cycling and
self-renewal capacity,12,18,19 we next asked whether the growth-
suppressing effects of KLF7 on HSPCs are mediated by CDKN1A.
Surprisingly, no change in Cdkn1a mRNA expression was ob-
served in KLS cells transduced with KLF7 lentivirus (Figure 5A).
We then repeated the in vitro growth assay and bone marrow
repopulating assays using Cdkn1a/ hematopoietic cells. Similar
to WT cells, significantly fewer KLF7 transduced Cdkn1a/ cells
formed colonies compared with controls (Figure 5B). Furthermore,
hematopoietic reconstitution by KLF7 transduced Cdkn1a/ cells
was markedly impaired. Again, we observed a relative preservation
of T cells, which, although still significantly lower that input levels,
were less repressed that other lineages (Figure 5C-E). Thus, the
effects of KLF7 on the suppression of cell growth and marrow
reconstitution are not dependent on CDKN1A.
KLF7 overexpression induces genes associated with
lymphocyte development
Because KLF7 is a transcription factor, we performed RNA
expression profiling on KLF7 transduced HSPCs to address the
mechanisms by which KLF7 inhibits HSPC function. GFP KLS
cells were isolated by sorting 72 hours after transduction of
c-Kit-selected WT bone marrow cells and RNA expression
profiling was performed using the Affymetrix MoGene 1.0ST
array. Using a false discovery rate of  10% and a criteria of a
minimum of 2-fold difference in expression, 75 genes were
identified whose expression was increased by KLF7 expression and
14 that were decreased (supplemental Table 3). Notably, the list of
up-regulated genes includes the previously described KLF7 targets
Tuba1a and L1cam,20,21 both of which are direct transcriptional
targets of KLF7 that are important for neurogenesis. However,
expression of the most well-characterized growth regulatory fac-
tors induced by KLF7, Cdkn1a and Cdkn1b (p27, kip-1),8 were not
significantly different between the KLF7-transduced and control
samples. Among the enriched gene sets, gene set enrichment
analysis identified significant enrichment for NF-B and T cell
receptor signaling pathways (supplemental Figure 3). However,
with the exception of the thymic homing receptor CCR7, no
significant difference in the expression of genes known to play a
significant role in the determination of T-cell fate or thymic
homing22,23 was observed between control and KLF7-overexpressing
cells (supplemental Table 4).
Figure 3. KLF7 overexpression inhibits bone marrow
reconstitution. (A) Bone marrow cells transduced with
MSCV expressing KLF7 or vector alone were trans-
planted into lethally irradiated recipients, and peripheral
blood was analyzed 6 and 12 weeks after transplantation.
Transduction efficiency was determined by measuring
the percentage of GFP KLS cells just before transplan-
tation (72 hours after viral exposure, time 	 0). Data
represent 2 individual experiments with 3-5 mice per
genotype per experiment. *P  .001. (B) Shown is the
percentage of donor B cells (B220), T cells (CD3e),
and neutrophils (Gr-1 high) that were GFP from 1 represen-
tative experiment. *P  .01. (C) Bone marrow cells were
transduced with HIV-MND–expressing KLF7 or vector
alone at a low multiplicity of infection were transplanted
into irradiated congenic recipients and the percentage
GFP leukocytes in the blood measured. Data represent
3 independent experiments. *P  .001. **P  .05. (D) The
percentage of donor B cells (B220), T cells (CD3e),
and neutrophils (Gr-1 high) that were GFP at 6 weeks
after transplantation. *P  .05. **P  .01. ***P  .0001.
(E) GFP cells were sorted 72 hours after viral transduc-
tion and RNA analyzed by real-time RT-PCR for KLF7
expression. Data are normalized to -actin and represent
2 independent experiments. *P 	 .043. (F) To assess
homing, GFP KLS cells were transplanted into irradi-
ated recipients and the number of GFP cells recovered
from the bone marrow 20 hours later determined. Shown
are the number of GFP cells per 106 whole bone marrow
cells, corrected for the number of cells injected. Data
represent 3 individual experiments, with 3-6 mice per
condition.
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KLF7 overexpression promotes survival of DN thymocytes
To further elucidate the role of KLF7 in T-cell development, we
analyzed T-cell subsets in the blood, spleen, and thymus in mice
transplanted with KLF7 or control transduced bone marrow (Figure
6A-B). Although GFP T cells in the blood and spleen were
significantly lower than input GFP values, they were higher than
GFP CLPs (Figure 4C). In the thymus, none of the T-cell subsets
analyzed (DN, DP, CD4 SP, and CD8 SP) was significantly
different from input values (Figure 6B). Thus, whereas enforced
expression of KLF7 suppresses bone marrow stem and progenitor
populations (including CLPs), thymic, and to some extent splenic
and blood, T cells are preserved. We next examined the effect of
KLF7 overexpression on thymocyte survival (Figure 6C-D). En-
forced expression of KLF7 resulted in the significant suppression
of apoptosis in DN thymocytes. Conversely, in later stages of
thymocyte development (DP, CD4 SP, and CD8 SP), a trend to
increased apoptosis is observed.
To address whether KLF7 is necessary for T-cell development,
we analyzed blood, splenic, and thymic T cells in the Klf7/ fetal
liver chimeras. No differences were noted between the frequencies
of CD4 SP and CD8 SP populations among the Klf7/ cells and
Klf7/ cells in the blood and spleens of the chimeric mice, and
similarly there were no significant differences in the frequencies of
the T-cell precursors in the thymus (supplemental Figure 4). The
possibility remains, however, that more subtle defects in T-cell
development may occur in the absence of KLF7, and the possible
contribution of KLF7 to T-cell development and/or trafficking
warrants further investigation.
Discussion
Although there is considerable evidence that KLF family members
regulate specific hematopoietic lineages, there are limited data
about their contribution to HSC maintenance. Matsumoto et al
reported that loss of KLF6 impaired yolk sac hematopoiesis and,
conversely, that overexpression of KLF6 resulted in enhanced
hematopoietic potential of embryonic stem cells.9 Moreover, there
is evidence that KLF4, KLF2, and KLF5 support self-renewal of
embryonic stem cells, and expression of KLF4, in conjunction with
Oct4, Sox2, and c-Myc, is widely used to reprogram somatic cells
to induced pluripotent stem cells.24,25 Jiang et al demonstrated that
KLF4, KLF2, and KLF5 play redundant roles in maintaining
embryonic stem cells, sharing many common targets, and loss of all
3 factors simultaneously was required to induce differentiation of
embryonic stem cells.25 Herein, we show that enforced expression
of KLF7 results in impaired myeloid differentiation and decreased
HSC activity in mice. However, KLF7 does not appear to be
required for normal HSC function, as the long-term repopulating
activity and self-renewal of Klf7/ cells are comparable to
WT cells. Given the redundancy of KLF family members in
Figure 4. KLF7 overexpression suppresses hematopoietic stem and progenitors. Bone marrow stem and progenitor populations were analyzed by flow cytometry
6 weeks after transplantation with control or KLF7 lentivirally transduced cells. (A) Gating strategy used to identify HSCs (KLS CD34), common myeloid progenitors (CMP,
Lin c-Kit Sca-1 CD16/32lo CD34), granulocyte-monocyte progenitors (GMPs, Lin C-Kit Sca-1 CD16/32hi CD34), and megakaryocytic-erythroid progenitors (MEP,
Lin c-Kit Sca-1 CD16/32lo CD34; top panel) and common lymphoid progenitors (CLP, Lin CD27 IL7R Flk-2 Ly6D; bottom panel). Cells are first gated on live, donor,
and lineage-negative populations. (B) Representative histograms showing GFP expression in the indicated progenitor cell population. (C) A summary of the percentages of
donor cells that are GFP for the indicated progenitor population is provided. Input refers the percentage of bone marrow cells that were GFP at the time of transplantation.
Data represent the mean  SEM of 2 independent experiments. ***P  .001.
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regulating embryonic stem cells, however, and the fact that we
detect expression of the majority of the KLF family members in
HSCs, it is quite possible that other KLFs may compensate for the
loss of KLF7 in regulating HSC function.
The molecular mechanisms by which KLF7 overexpression
suppresses HSC function are not known. KLF7 has been shown to
induce the expression of CDKN1A and CDKN1B, and thus we
predicted that the growth inhibitory of effects of KLF7 is probably
mediated by these factors. Contrary to this idea, we found that
neither of these genes were up-regulated on overexpression of
KLF7, and we observed a similar suppression of hematopoiesis in
the Cdkn1a/ cells with overexpression of KLF7 compared with
WT cells. Therefore, the growth suppressive effects of KLF7 in
HSPCs are not mediated by CDKN1A, and other targets of KLF7
in these cells are responsible for inhibiting HSPC proliferation.
Interestingly, RNA profiling of KLF7 overexpressing HSPCs did
not reveal a dysregulation of other genes known to regulate HSC
activity. Given the heterogeneous nature of the KLS HSPC
population, the identification of KLF7 targets conferring growth
suppression in HSCs may require profiling of a further enriched
HSC population after induction of KLF7 expression. Furthermore,
as discussed later in the “Discussion,” enforced KLF7 expression
in HSPCs is associated with an up-regulation of genes involved in
lymphocyte development, and thus perhaps the suppression of
HSCs is the result of differentiation of KLF7 overexpressing cells
toward the lymphocytic lineage.
Relative to HSCs and CLPs, T-cell production is preserved in
mice transplanted with KLF7 overexpressing cells, implicating, for
the first time, a role for KLF7 in T-cell development. Interestingly,
in a profiling study of thymocyte subpopulations, Tabrizifard et al
reported up-regulation of KLF7 during the preDP to smDP
transition.26 This transition involves a switch from active cell
proliferation to cell cycle arrest, allowing for selection and further
differentiation of cells with T-cell receptors of the correct specific-
ity. In agreement with this finding, our own quantitative RT-PCR
data show a 5-fold increase in KLF7 mRNA expression from the
DN to DP stage (supplemental Figure 1). Further supporting a role
for KLF7 in T-cell development, our RNA profiling of KLF7
overexpressing HSPCs identified up-regulation of a number of
genes that play a role in lymphocyte development and activation,
including Ccl22, Pira2, Pira3, Pira11, Lilrb3, Ccl17, H2-Aa, Ccr1,
Cd83, and H2-DMb2, as well as antiapoptotic factors, including
Serpinb9, Spp1, Traf1, and Bcl2a1. On the other hand, Klf7/ cells
produce a grossly similar profile of T-cell subsets to Klf7/ cells,
suggesting that KLF7 is not absolutely necessary for T-cell
development. However, the mice used in these analyses were
4-10 months after transplantation; therefore, a role for KLF7 in
early thymic development remains a possibility. Moreover, numer-
ous other KLF family members, including KLF2, KLF4, KLF5,
KLF6, KLF10, and KLF13, have been implicated in T-cell
development.7 Thus, redundancy in KLF function, with compensa-
tion for KLF7 loss by another family member, could explain the
ability of Klf7/ cells to produce a normal T-cell profile.
Flotho et al identified KLF7 as 1 of 14 genes that independently
predicted therapy resistance and relapse of ALL in a large cohort of
pediatric patients.2 Notably, inhibition of the cell cycle and DNA
replication was a common function of many of the dysregulated
genes in that study, indicating that suppression of leukemic cell
growth may contribute to chemotherapy resistance. Of particular
note is an up-regulation of B-cell lymphoma 2-related protein A1
(Bcl2a1) on enforced expression of KLF7 (real-time RT-PCR
confirmed an  2-fold increase in expression of Bcl2a1 in KLS
cells overexpressing KLF7; data not shown). Bcl2a1 is a pro-
survival member of the BCL2 family, and it has been previously
been shown to be a pre-T cell receptor–induced regulator of
thymocyte survival. Enhanced expression of BCL2A1 has been
Figure 5. KLF7 suppression of HSPC function is not mediated by CDKN1A. (A) Cdkn1a mRNA expression relative to -actin in GFP KLS cells 72 hours after transduction
with lentivirus expressing KLF7 or vector alone. (B) Bone marrow cells exposed to KLF7 or control lentivirus were plated in methylcellulose and colonies scored on day 7. The
percentage of GFP colonies is shown, normalized for the transduction efficiency. Data represent 2 independent experiments, plated in duplicate. *P 	 .0002. Cdkn1a/ bone
marrow was transduced with KLF7 or control lentivirus and transplanted into irradiated congenic recipients. Six weeks after transplantation, the percentage of donor leukocytes
(C), cells of the indicated hematopoietic lineage (D), or indicated progenitor cell population (E) that was GFP was determined. Time zero in panel C refers to the transduction
efficiency. Input indicates the percentage of GFP cells at the time of transplantation. Data represent 2 individual experiments, each with 5 or 6 mice per genotype. *P  .01.
**P  .05. ***P  .0001.
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described in multiple tumor types, including leukemias and lympho-
mas,27 and overexpression is associated with chemotherapy-
resistant and advanced disease.28,29 Furthermore, overexpression of
BCL2A1 in cell lines has been shown to confer chemotherapy
resistance,30-32 and conversely knockdown of BCL2A1 was found
to sensitize malignant B-cell lines to chemotherapy-induced apopto-
sis.33 Small-molecule inhibitors of BCL2A1 are currently being
tested in multiple cancers, including leukemia.27 The up-regulation
of BCL2A1 and other antiapoptotic and growth regulatory factors
on KLF7 overexpression suggests that KLF7 may contribute to
therapy resistant disease by promoting lymphocyte survival. In-
deed, our data show that KLF7 overexpression leads to reduced
apoptosis of DN thymocytes, further supporting the idea that
aberrantly high KLF7 expression in lymphoblastic leukemic cells
may contribute to enhanced survival and resistance to chemo-
therapy. Finally, BCL2A1 is a target of NF-B, and significant
up-regulation of this pathway was identified by gene set enrich-
ment analysis in KLF7-overexpressing HSPCs. Activation of this
pathway plays a crucial role in normal lymphopoiesis, and
enhanced NF-B activity is associated with numerous lymphoid
and myeloid malignancies.34
Taken together, this study suggests that KLF7, although not
necessary for normal HSPC repopulating and self-renewal activi-
ties, may play a role in regulating thymocyte development.
Overexpression of KLF7, as seen in resistant leukemia, inhibits
normal HSPC function and supports early thymocyte survival.
Future studies will be aimed at determining the direct targets of
KLF7 in hematopoietic cells, identifying the growth suppressing
factors mediated by KLF7 in HSPCs and the role of KLF7 in
thymocyte development. This information will allow for a better
understanding of the role of KLF7 in normal lymphopoiesis and in
leukemia. Ultimately, inhibition of KLF7 or its downstream targets
could then potentially be used to sensitize chemotherapy-resistant
cells, providing a targeted approach to the treatment of refractory or
relapsed leukemia.
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